About Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc., founded in 1996, has successfully transitioned from a discovery-stage company to a commercial-stage biopharmaceutical company with approved products generating revenue. The company focuses on developing therapies for immune and hematologic disorders where significant unmet medical needs exist. RIGL stock price reflects both current product revenues and pipeline potential in large therapeutic markets.

Led by CEO Raul Rodriguez, Rigel has built commercial capabilities while continuing to advance its research pipeline. The management team combines drug development expertise with commercial execution experience, positioning the company for sustainable growth. Leadership's strategic focus on expanding indications for approved products while advancing novel pipeline candidates has been important for creating multiple value drivers affecting RIGL stock price.

Rigel operates with approved products including TAVALISSE for chronic immune thrombocytopenia and REZLIDHIA for acute myeloid leukemia, while developing additional candidates for inflammatory and autoimmune conditions. The company's expertise in kinase inhibition has yielded a productive discovery platform generating multiple clinical candidates. With established commercial products providing revenue, opportunities to expand into additional indications and geographies, and a pipeline addressing large market opportunities, RIGL offers investors a differentiated small-cap biotechnology investment with both current revenues and significant growth potential from pipeline advancement.